Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites

Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites

**Design**

- **Study**
  - Prospective, multicenter, phase 3 trial
  - 16 centers in Southeastern United States

- **Subjects**
  - N = 200 adults with chronic HCV (100 blacks and 100 non-Hispanic whites)
  - Treatment naïve
  - HCV genotype (98% with genotype 1)

- **Regimens (Ribavirin Dosed by Weight)**
  - Peginterferon alfa-2b: 1.5 µg/kg 1x/week x 48 weeks +
    - Ribavirin 1000 mg/day for weeks 1-12, then 800 mg/day for weeks 13-48

- **Primary Endpoint (Sustained Virologic Response [SVR])**
  - SVR = Undetectable serum HCV RNA 24 weeks after 48-week treatments

Peginterferon alfa-2b + Ribavirin in Blacks and Non-Hispanic Whites

Results

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>48</th>
<th>72</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 100</td>
<td>Peginterferon alfa-2b + Ribavirin</td>
<td>Blacks</td>
<td>SVR24</td>
</tr>
<tr>
<td>N = 100</td>
<td>Peginterferon alfa-2b + Ribavirin</td>
<td>Non-Hispanic Whites</td>
<td>SVR24</td>
</tr>
</tbody>
</table>

Drug Dosing
Peginterferon alfa-2b: 1.5 μg/kg 1x/week
Ribavirin (divided bid): 1000 mg/day x weeks 1-12, then 800 mg/day for weeks 13-48

Peginterferon alfa-2b + Ribavirin in Blacks and Non-Hispanic Whites

Results

Virologic Responses by Race

Conclusions: “Black patients with chronic hepatitis C have a lower rate of response to treatment with peginterferon alfa-2b and ribavirin than non-Hispanic white patients, a difference that is not explained by differences in the viral genotype.”

This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

**Hepatitis C Online**

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

**Hepatitis Web Study**


Funded by a grant from the Centers for Disease Control and Prevention.